| dc.contributor.author | Geddes, John R | |
| dc.date.accessioned | 2022-07-07T20:44:02Z | |
| dc.date.available | 2022-07-07T20:44:02Z | |
| dc.date.issued | 2022-03 | |
| dc.identifier.citation | De Picker, L., Leboyer, M., Geddes, J., Morrens, M., Harrison, P., & Taquet, M. (2022). Association between serum lithium level and incidence of COVID-19 infection. The British Journal of Psychiatry, 221(1), 425-427 | en |
| dc.identifier.uri | https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/1086 | |
| dc.description | Available with an NHS OpenAthens log in for eligible users | en |
| dc.description.abstract | An antiviral effect of lithium has been proposed, but never investigated for coronavirus disease 2019 (COVID-19). Using electronic health records of 26 554 patients with documented serum lithium levels during the pandemic, we show that the 6-month COVID-19 infection incidence was lower among matched patients with ‘therapeutic’ (0.50–1.00) versus ‘subtherapeutic’ (0.05–0.50) lithium levels (hazard ratio (HR) = 0.82, 95% CI 0.69–0.97, P = 0.017) and among patients with ‘therapeutic’ lithium levels versus matched patients using valproate (HR = 0.79, 95% CI 0.67–0.92, P = 0.0023). Lower rates of infection were observed for both new COVID-19 diagnoses and positive polymerase chain reaction tests, regardless of underlying psychiatric diagnosis and vaccination status. | en |
| dc.description.uri | https://doi:10.1192/bjp.2022.42 | en |
| dc.language.iso | en | en |
| dc.subject | COVID-19 | en |
| dc.subject | Lithium | en |
| dc.title | Association between serum lithium level and incidence of COVID-19 infection | en |
| dc.type | Article | en |